{"id":148703,"date":"2026-10-23T07:52:23","date_gmt":"2026-10-23T07:52:23","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/148703\/"},"modified":"2026-10-23T07:52:23","modified_gmt":"2026-10-23T07:52:23","slug":"roche-signs-drug-discovery-deal-with-atavistik-bio-worth-up-to-2-billion-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/148703\/","title":{"rendered":"Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Sept 24 (Reuters) &#8211; Drug developer Atavistik Bio said on Thursday it has signed a deal with \u200cSwiss drugmaker Roche potentially worth nearly $2 billion, \u200cincluding milestone payments, to develop oral treatments for cardiovascular, kidney and \u200bmetabolic diseases.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Here are some details:  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 As part of the agreement, Atavistik will receive $70 million upfront and could get up to $1.9 billion in research, development and commercial milestone payments, \u200cplus royalties on \u2060sales of approved drugs, the privately held drug developer said.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 The partnership covers multiple \u2060drug targets and will use Atavistik&#8217;s proprietary technology to find hidden pockets on disease-causing proteins, potentially allowing drugs to \u200bbe developed \u200bagainst targets conventional methods \u200bhave struggled to reach.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 \u200cUnlike many traditional drugs that bind to a protein&#8217;s main active site, Atavistik&#8217;s approach targets other sites that regulate how the protein works, which could allow for more selective treatments with fewer unintended effects.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 Atavistik will \u200clead early discovery and research, \u200bwhile Roche will handle further \u200blab and human \u200btesting, regulatory filings and commercialization, Atavistik said.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 \u200cAtavistik will continue developing its \u200bown treatments for \u200brare blood disorders, including for hereditary hemorrhagic telangiectasia, which causes malformed blood vessels.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">\u2022 The companies did \u200bnot disclose the \u200cnumber of targets covered by the partnership or \u200bprovide development timelines.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">(Reporting by Kunal Das in \u200bBengaluru; Editing by Pooja Desai)  <\/p>\n","protected":false},"excerpt":{"rendered":"Sept 24 (Reuters) &#8211; Drug developer Atavistik Bio said on Thursday it has signed a deal with \u200cSwiss&hellip;\n","protected":false},"author":2,"featured_media":148704,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[65431,65446,65447,65445,8206,9370,19411,134],"class_list":["post-148703","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-atavistik","tag-atavistik-bio","tag-drug-developer","tag-drug-targets","tag-metabolic-diseases","tag-milestone-payments","tag-proprietary-technology","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117489142830952022","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/148703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=148703"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/148703\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/148704"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=148703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=148703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=148703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}